Literature DB >> 33407513

Hydrophobic insertion-based engineering of tumor cell-derived exosomes for SPECT/NIRF imaging of colon cancer.

Boping Jing1,2, Yongkang Gai1,2, Ruijie Qian1,2, Zhen Liu1,2, Ziyang Zhu1,2, Yu Gao1,2, Xiaoli Lan3,4, Rui An5,6.   

Abstract

BACKGROUND: Tumor cell-derived exosomes (TEx) have emerged as promising nanocarriers for drug delivery. Noninvasive multimodality imaging for tracing the in vivo trafficking of TEx may accelerate their clinical translation. In this study, we developed a TEx-based nanoprobe via hydrophobic insertion mechanism and evaluated its performance in dual single-photon emission computed tomography (SPECT) and near-infrared fluorescence (NIRF) imaging of colon cancer.
RESULTS: TEx were successfully isolated from HCT116 supernatants, and their membrane vesicle structure was confirmed by TEM. The average hydrodynamic diameter and zeta potential of TEx were 110.87 ± 4.61 nm and -9.20 ± 0.41 mV, respectively. Confocal microscopy and flow cytometry findings confirmed the high tumor binding ability of TEx. The uptake rate of 99mTc-TEx-Cy7 by HCT116 cells increased over time, reaching 14.07 ± 1.31% at 6 h of co-incubation. NIRF and SPECT imaging indicated that the most appropriate imaging time was 18 h after the injection of 99mTc-TEx-Cy7 when the tumor uptake (1.46% ± 0.06% ID/g) and tumor-to-muscle ratio (8.22 ± 0.65) peaked. Compared with radiolabeled adipose stem cell derived exosomes (99mTc-AEx-Cy7), 99mTc-TEx-Cy7 exhibited a significantly higher tumor accumulation in tumor-bearing mice.
CONCLUSION: Hydrophobic insertion-based engineering of TEx may represent a promising approach to develop and label exosomes for use as nanoprobes in dual SPECT/NIRF imaging. Our findings confirmed that TEx has a higher tumor-targeting ability than AEx and highlight the potential usefulness of exosomes in biomedical applications.

Entities:  

Keywords:  Colon cancer; Hydrophobic insertion; SPECT/NIRF imaging; Tumor cell-derived exosomes

Year:  2021        PMID: 33407513     DOI: 10.1186/s12951-020-00746-8

Source DB:  PubMed          Journal:  J Nanobiotechnology        ISSN: 1477-3155            Impact factor:   10.435


  7 in total

1.  FGD3 binds with HSF4 to suppress p65 expression and inhibit pancreatic cancer progression.

Authors:  Feng Guo; Xiang Cheng; Boping Jing; Heshui Wu; Xin Jin
Journal:  Oncogene       Date:  2022-01-03       Impact factor: 9.867

2.  Multi-antitumor therapy and synchronous imaging monitoring based on exosome.

Authors:  Ruijie Qian; Boping Jing; Dawei Jiang; Yongkang Gai; Ziyang Zhu; Xiaojuan Huang; Yu Gao; Xiaoli Lan; Rui An
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-29       Impact factor: 10.057

Review 3.  Recent advances in targeted drug delivery systems for resistant colorectal cancer.

Authors:  Masoumeh Sharifi-Azad; Marziyeh Fathi; William C Cho; Abolfazl Barzegari; Hamed Dadashi; Mehdi Dadashpour; Rana Jahanban-Esfahlan
Journal:  Cancer Cell Int       Date:  2022-05-19       Impact factor: 6.429

4.  Cell membrane camouflaged biomimetic nanoparticles: Focusing on tumor theranostics.

Authors:  Li Zhu; Yuan Zhong; Shuai Wu; Meng Yan; Yu Cao; Nianlian Mou; Guixue Wang; Da Sun; Wei Wu
Journal:  Mater Today Bio       Date:  2022-03-01

Review 5.  NIR-I Dye-Based Probe: A New Window for Bimodal Tumor Theranostics.

Authors:  Fan Zheng; Xueyan Huang; Jipeng Ding; Anyao Bi; Shifen Wang; Fei Chen; Wenbin Zeng
Journal:  Front Chem       Date:  2022-03-23       Impact factor: 5.221

6.  PET Imaging of Small Extracellular Vesicles via [89Zr]Zr(oxinate)4 Direct Radiolabeling.

Authors:  Azalea A Khan; Francis Man; Farid N Faruqu; Jana Kim; Fahad Al-Salemee; Amaia Carrascal-Miniño; Alessia Volpe; Revadee Liam-Or; Paul Simpson; Gilbert O Fruhwirth; Khuloud T Al-Jamal; Rafael T M de Rosales
Journal:  Bioconjug Chem       Date:  2022-02-28       Impact factor: 4.774

Review 7.  Tumor-derived small extracellular vesicles: potential roles and mechanism in glioma.

Authors:  Xu Guo; Rui Sui; Haozhe Piao
Journal:  J Nanobiotechnology       Date:  2022-08-23       Impact factor: 9.429

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.